Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01479244
Title Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements No
Sponsors Galena Biopharma, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

E75

Sargramostim

Age Groups: adult
Covered Countries USA | FRA | DEU | CAN


No variant requirements are available.